Sylvia Rodriguez, APRN
Family · Edinburg, TXNPI 1053859728
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.1%), education and other — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Novartis at 27.4% of the total. Reporting peaked in 2024 at $866 and has fallen 63.4% since, to $317 in 2025.
Across 107 payments — averaging $26.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$780
- Astellas Pharma US Inc$448
- Pfizer$140
- GSK$135
- Eisai Inc.$109
- Lilly USA, LLC$108
- plus $1K from 28 others
What the payments were for
- Food & beverage$1,65458%
- Education$64123%
- Other$54919%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $780 |
| Astellas Pharma US Inc | 11 | $448 |
| Pfizer | 7 | $140 |
| GSK | 7 | $135 |
| Eisai Inc. | 5 | $109 |
| Lilly USA, LLC | 2 | $108 |
| Bristol Myers Squibb | 5 | $107 |
| Incyte Corporation | 1 | $100 |
| Boston Scientific | 4 | $100 |
| Amgen | 6 | $83 |
| Johnson & Johnson(2 entities) | 5 | $73 |
| AbbVie | 3 | $61 |
| Sanofi | 3 | $50 |
| Genentech USA, Inc. | 2 | $44 |
| Karyopharm Therapeutics Inc. | 2 | $42 |
| Taiho Oncology, Inc. | 2 | $41 |
| Merck | 2 | $40 |
| Seagen Inc. | 2 | $37 |
| Sobi, Inc | 2 | $37 |
| AstraZeneca | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Tempus AI, Inc | 1 | $29 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Tersera Therapeutics LLC | 1 | $19 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Array Biopharma Inc | 1 | $17 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Gilead | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Morphosys, US Inc. | 1 | $13 |
How this compares
$2,845 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 44 | $495 |
Paid to pharmacies, not to this prescriber.
Other family in Edinburg
- Mayra CantazaroEdinburg$150K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.